Online inquiry

IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3741MR)

This product GTTS-WQ3741MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3741MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11388MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ678MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ3294MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ15359MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ7074MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ281MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ1304MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ14362MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW